Close

pCDCAR1 EGFRvIII h(BBζ) (CAR-LC055)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to 4-1BB (CD137) and CD3ζ signaling domains. And the vector product was designed for the treatment of glioblastoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFRvIII
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Glioblastoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 3C10
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • epidermal growth factor receptor
  • Synonyms
  • ERBB; HER1; mENA; ERBB1; PIG61; NISBD2;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Flow cytometry analysis of SMAD2/3 phosphorylation induced by TGFβ in anti-EGFRvIII CAR or TGFβ-trapped anti-EGFRvIII CAR T cells.

CAR Construction : 3C10 scFv-BBζ Latest CAR Construction

Fig.1 Flow cytometry analysis of SMAD2/3 phosphorylation induced by TGFβ in anti-EGFRvIII CAR or TGFβ-trapped anti-EGFRvIII CAR T cells.

Functional characterization of TGFβ-trapped EGFRvIII-specific CAR T cells.

Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117.

Complete CAR data Cyt

Fig.2 Cytotoxicity of mock CAR-Ts, anti-EGFRvIII (3C10) CAR-Ts, TGFβ-trapped anti-EGFRvIII CAR (3C10CAR-TGFRII) T cells against EGFRvIII+ target cells in the presence or absence of TGFβ.

CAR Construction : 3C10 scFv-BBζ Latest CAR Construction

Fig.2 Cytotoxicity of mock CAR-Ts, anti-EGFRvIII (3C10) CAR-Ts, TGFβ-trapped anti-EGFRvIII CAR (3C10CAR-TGFRII) T cells against EGFRvIII+ target cells in the presence or absence of TGFβ.

Functional characterization of TGFβ-trapped EGFRvIII-specific CAR T cells.

Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117.

Complete CAR data FuncS

Fig.3 TGFβ-trapped anti-EGFRvIIII CAR-T more effectively controls tumor growth in orthotopic GBM models.

CAR Construction : 3C10 scFv-BBζ Latest CAR Construction

Fig.3 TGFβ-trapped anti-EGFRvIIII CAR-T more effectively controls tumor growth in orthotopic GBM models.

Kaplan-Meier survival curves of U87-EGFRvIII-luc-bearing mice treated with different CAR-Ts.

Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117.

Complete CAR data FCM

Fig.4 TGFβ-trapped CAR-T treatment increased CAR-Ts infiltration and convert infiltrated-microglia to pro-inflammatory phenotype.

CAR Construction : 3C10 scFv-BBζ Latest CAR Construction

Fig.4 TGFβ-trapped CAR-T treatment increased CAR-Ts infiltration and convert infiltrated-microglia to pro-inflammatory phenotype.

Representative dot plots showing the proportion of infiltrated hCD3+ CAR-T cells in cells suspension (left); quantification of CD3+T cell infiltration in different treatment groups (right).

Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117.

Complete CAR data IHC

Fig.5 Immunohistochemistry of IbaI+ microglia in glioma tissue showing the number of infiltrated microglia increased in 3C10CAR-TGFRII group and morphology change (red arrow).

CAR Construction : 3C10 scFv-BBζ Latest CAR Construction

Fig.5 Immunohistochemistry of IbaI+ microglia in glioma tissue showing the number of infiltrated microglia increased in 3C10CAR-TGFRII group and morphology change (red arrow).

In contrast to the ramified appearance of that in the mock CAR group, infiltrated microglia in the 3C10CAR-TGFRII group had morphology change and showed soma enlargement and process retraction.

Li, Y., Wu, H., Chen, G., Wei, X., Wang, C., Zhou, S., ... & Ying, T. (2020). Arming anti-EGFRvIII CAR-T with TGFβ trap improves antitumor efficacy in glioma mouse models. Frontiers in oncology, 10, 1117.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFRvIII (3C10) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC055). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.